Similar articles

• Ligand-based vascular targeting of disease.

  Rybak JN, Trachsel E, Scheuermann J, Neri D. Rybak JN, et al. ChemMedChem. 2007 Jan;2(1):22-40. doi: 10.1002/cmdc.200600181. ChemMedChem. 2007. PMID: 17154429 Review.
• Clinical development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors: what lessons have we learned?

  Hidalgo M. Hidalgo M. Adv Exp Med Biol. 2008;610:128-43. doi: 10.1007/978-0-387-73898-7_10. Adv Exp Med Biol. 2008. PMID: 18593020 Review. No abstract available.
• At the flick of a switch: epigenetic drugs.

  Pray L. Pray L. Chem Biol. 2008 Jul 21;15(7):640-1. doi: 10.1016/j.chembiol.2008.07.003. Chem Biol. 2008. PMID: 18634998 No abstract available.
• Beyond VEGF: targeting tumor growth and angiogenesis via alternative mechanisms.

  Christensen J, Anderes K. Christensen J, et al. Adv Exp Med Biol. 2008;610:43-53. doi: 10.1007/978-0-387-73898-7_4. Adv Exp Med Biol. 2008. PMID: 18593014 Review. No abstract available.
• Targeted therapies in cancer: myth or reality? Introduction.

  Colotta F, Mantovani A. Colotta F, et al. Adv Exp Med Biol. 2008;610:v-vi. Adv Exp Med Biol. 2008. PMID: 18593010 No abstract available.